Mi az ára TME Pharma N.V. (ALTME)

TME Pharma N.V. (ALTME) ára $0.0794724

Mi a TME Pharma N.V. (ALTME piaci tőkésítése)

TME Pharma N.V. piaci tőkésítése (ALTME) $7.49M

TME Pharma N.V. (ALTME) Ár és Piaci Kapitalizáció

TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.

A ALTME ára	B aktíva	A B piaci tőkésítése	Eredmények
$57,880.04 $7.49M	NVDA	$5.452T	+72,830,275.53%
$47,668.54 $7.49M	AAPL	$4.490T	+59,981,152.49%
$44,190.42 $7.49M	GOOG	$4.162T	+55,604,636.05%
$39,030.09 $7.49M	MSFT	$3.676T	+49,111,399.68%
$30,077.15 $7.49M	AMZN	$2.833T	+37,845,931.57%

A ALTME ára

B aktíva

A B piaci tőkésítése

Eredmények

$57,880.04 $7.49M